Experts
Prescient Therapeutics (ASX:PTX) develop novel, personalised therapies for a range of cancers.
Prescient’s CAR-T and targeted therapies are personalised medicine approaches that aim to improve patient outcomes.
Prescient has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Prescient has licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.
Prescient Therapeutics is working to rapidly expand the application of universal CAR-T therapies, capable of addressing all cancers, including solid tumours.
OmniCAR, a universal CAR-T platform employing technology licensed from UPenn, the pioneer and world leader in CAR-T, as well as Oxford University, will allow unprecedented control and flexibility over current generation CAR-T approaches. It combines the cancer-killing capabilities of a T-cell with the control and pharmacology of a drug.
CellPryme-M is a high-performance platform for enhancing cell therapy manufacturing that results in cell products with superior phenotypes that are longer lasting and more efficacious. It involves a single, rapid step that can be easily accommodated within standard cell manufacturing protocols. CellPryme-M was developed by Prescient in collaboration with the Peter MacCallum Cancer Centre, with Prescient retaining whole ownership of intellectual property.
Further to this, Prescient is working with leading CAR-T innovators to develop other improved CAR-T approaches.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Cancer fighter Prescient navigates challenging conditions for biotech, reports strong Q1 FY24
Health & Biotech
Prescient prepares to unveil Phase 1b cancer trial findings at world’s largest haematology conference
News
In Case You Missed It: Lithium and gold project acquisitions and cheaper boron nitride nanotubes
Explainers
ASX cancer stocks guide: Here’s everything you need to know
Health & Biotech
‘Above and beyond approved therapies’: How Prescient Therapeutics is at the forefront of cancer fighting
News
ASX Quarterly Wrap: Dimerix sees strong kidney drug trial recruitment, Prescient advances cancer therapy
Health & Biotech
Health Kick Podcast: Prescient Therapeutics an emerging global leader in the next generation of personalised cancer therapies.
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
News
ASX Quarterly Wrap: Growing pipeline, milestones, and bullish guidance were the themes for these stocks
Experts
CRITERION: The ASX cancer fighters with a sting in their treatment tails
Health & Biotech
Health Kick Podcast: Prescient Therapeutics’ PTX-100 continues to show encouraging results following FDA Orphan Drug Designation
Health & Biotech
Prescient Therapeutics hopes to accelerate bid for US FDA study approval for targeted therapy PTX-100
Health & Biotech
ASX Health Stocks: High fives as Telix gets expanded FDA approval, Prescient’s PTX-100 returns good results
News
Rise and Shine: Everything you need to know before the ASX opens
News
Weekly Small Caps and IPO Wrap: Negging the US economy won’t make it pick up, Mr Powell.
News
Rise and Shine: Everything you need to know before the ASX opens
News